scholarly article | Q13442814 |
P6179 | Dimensions Publication ID | 1001969954 |
P356 | DOI | 10.1038/BMT.2010.64 |
P698 | PubMed publication ID | 20383212 |
P5875 | ResearchGate publication ID | 43100174 |
P2093 | author name string | K Sakashita | |
M Tanaka | |||
S Saito | |||
K Koike | |||
M Shiohara | |||
R Yanagisawa | |||
T Shigemura | |||
Y Nakazawa | |||
Y Katsuyama | |||
P2860 | cites work | Tacrolimus (FK506) and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation | Q31418325 |
Practical considerations in the use of tacrolimus for allogeneic marrow transplantation | Q33782457 | ||
Engraftment syndrome following hematopoietic stem cell transplantation | Q34298239 | ||
An up-date review on individualized dosage adjustment of calcineurin inhibitors in organ transplant patients | Q36499377 | ||
Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation | Q40385566 | ||
Anakinra improves sensory deafness in a Japanese patient with Muckle-Wells syndrome, possibly by inhibiting the cryopyrin inflammasome | Q40425731 | ||
Differential drug-induced mRNA expression of human CYP3A4 compared to CYP3A5, CYP3A7 and CYP3A43. | Q40658076 | ||
Phase III study comparing tacrolimus (FK506) with cyclosporine for graft-versus-host disease prophylaxis after allogeneic bone marrow transplantation | Q43710389 | ||
Low toxicity of a conditioning with 8-Gy total body irradiation, fludarabine and cyclophosphamide as preparative regimen for allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies | Q44137979 | ||
Neurotoxicity induced by tacrolimus after liver transplantation: relation to genetic polymorphisms of the ABCB1 (MDR1) gene | Q44157253 | ||
Tacrolimus Dosing in Pediatric Heart Transplant Patients is Related to CYP3A5 and MDR1 Gene Polymorphisms | Q44402549 | ||
FK-506 and cyclosporin A inhibit highly similar signal transduction pathways in human T lymphocytes | Q44729971 | ||
Tacrolimus clearance is age-dependent within the pediatric population | Q45871846 | ||
Influence of drug transporters and UGT polymorphisms on pharmacokinetics of phenolic glucuronide metabolite of mycophenolic acid in Japanese renal transplant recipients | Q46434574 | ||
Impact of MDR1 and CYP3A5 on the oral clearance of tacrolimus and tacrolimus-related renal dysfunction in adult living-donor liver transplant patients | Q46647761 | ||
A possible role for the production of multiple HLA antibodies in fatal platelet transfusion refractoriness after peripheral blood progenitor cell transplantation from the mother in a patient with relapsed leukemia | Q47575405 | ||
Dexamethasone modulation of multidrug transporters in normal tissues. | Q54106487 | ||
Regulation by dexamethasone of P-glycoprotein expression in cultured rat hepatocytes. | Q54235409 | ||
Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors | Q70051817 | ||
Increased clearance of tacrolimus in children: need for higher doses and earlier initiation prior to bone marrow transplantation | Q73338170 | ||
Lack of interaction between tacrolimus (FK506) and methotrexate in bone marrow transplant recipients | Q73533045 | ||
Tacrolimus pharmacokinetics in BMT patients | Q74256230 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 90-97 | |
P577 | publication date | 2010-04-12 | |
P1433 | published in | Bone Marrow Transplantation | Q4941523 |
P1476 | title | Engraftment syndrome, but not acute GVHD, younger age, CYP3A5 or MDR1 polymorphisms, increases tacrolimus clearance in pediatric hematopoietic SCT. | |
P478 | volume | 46 |
Q53706894 | A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients. |
Q38748975 | Clinical determinants of calcineurin inhibitor disposition: a mechanistic review |
Q26798470 | Role of Pharmacogenetics in Hematopoietic Stem Cell Transplantation Outcome in Children |
Q44133007 | Safety, tolerability, and feasibility of antifungal prophylaxis with micafungin at 2 mg/kg daily in pediatric patients undergoing allogeneic hematopoietic stem cell transplantation |
Q53175337 | Twice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation. |
Search more.